Treatment options for high-risk chronic lymphocytic leukaemia.

about

Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.

P2860

Q51007218-822F2D1E-D3F6-4EB0-A083-A41F11A295BD

P2860

Treatment options for high-risk chronic lymphocytic leukaemia.

Item

http://www.wikidata.org/entity/Q36612587

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Treatment options for high-risk chronic lymphocytic leukaemia.

@ast

Treatment options for high-risk chronic lymphocytic leukaemia.

@en

type

Item

label

Treatment options for high-risk chronic lymphocytic leukaemia.

@ast

Treatment options for high-risk chronic lymphocytic leukaemia.

@en

prefLabel

Treatment options for high-risk chronic lymphocytic leukaemia.

@ast

Treatment options for high-risk chronic lymphocytic leukaemia.

@en

P1476

Treatment options for high-risk chronic lymphocytic leukaemia.

@en

P2093

Saman Hewamana

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

P304

147-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620711404469

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Claire E. Dearden

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236106943

http://www.w3.org/2001/XMLSchema#string

P698

23556086

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

lymphocyte

P932

3573406

http://www.w3.org/2001/XMLSchema#string

Treatment options for high-risk chronic lymphocytic leukaemia.

about

P2860

P2860

Treatment options for high-risk chronic lymphocytic leukaemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932